Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism

RYE, N.Y., May 3 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Keystone Symposia meeting, Toward Defining the Pathophysiology of Autistic Behavior, held in April in Snowbird, Utah.
 

Fallon presented on "The Role of Protein Assimilation and Utilization in Children with Autism." She discussed Curemark's research exploring a possible link between a lack of protein-digesting enzymes in autistic children, necessary for the production of amino acids needed for brain function, and the symptoms of autism.
 

"The Keystone Symposia meeting provided an excellent forum to share our research with others in the scientific community who are attempting to understand the physiological causes of autism and working to develop possible therapies," Fallon said.
 

Curemark is in the midst of Phase III clinical trials for CM-AT, its autism treatment targeted as enzyme replacement therapy. CM-AT recently was designated as a Fast Track drug by the FDA.
 

Keystone Symposia on Molecular and Cellular Biology is a non-profit organization with a 38-year history of organizing conferences to connect the scientific community and accelerate scientific discoveries.
 

About CUREMARK LLC
 

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com
 

Safe Harbor Statement
 

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
 

Source: Curemark LLC

CONTACT: Michelle Manoff, Rubenstein Public Relations, 212-843-8051,
mmanoff@rubensteinpr.com; Dr. Joan Fallon, Curemark LLC, +1-914-925-3450,
joan.fallon@curemark.com
 

Posted: May 2010

View comments

Hide
(web4)